SCHEMBL14252003

SCHEMBL14252003

CCCCOC(=O)N(CCC(C)C)Cc1cc(F)c(Oc2ccc3c(c2)OC(C)(C)OC3=O)c(F)c1

nearest known ligand 0.35

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
LPAR1 Q92633 3/20 0.35
LPAR5 Q9H1C0 3/20 0.35
TDP1 Q9NUW8 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14252000 0.91 LPAR1 (0.41) LPAR1LPAR5
SCHEMBL4366116 0.87 LPAR1 (0.36) LPAR1LPAR5
SCHEMBL13632805 0.84 LPAR1 (0.34) LPAR1LPAR5
SCHEMBL14252009 0.79 LPAR1 (0.41) LPAR1LPAR5
SCHEMBL4355002 0.78 LPAR1 (0.42) LPAR1LPAR5
SCHEMBL13632839 0.78 LPAR1 (0.36) LPAR1LPAR5
SCHEMBL13632815 0.75 LPAR1 (0.40) LPAR1LPAR5
SCHEMBL4018263 0.74 ADRB2 (0.34) L3MBTL1
SCHEMBL13638403 0.72 LPAR1 (0.40) LPAR1LPAR5
SCHEMBL14217477 0.71 AKR1C3 (0.42) LPAR1LPAR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008032156-A1 DIARYL ETHER DERIVATIVES AND USES THEREOF PFIZER PRODUCTS INC. (US) 2008-03-20 WO disclosed
US-20080070887-A1 Diaryl Ether Derivatives and Uses Thereof PFIZER INC 2008-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070887-A1 Diaryl Ether Derivatives and Uses Thereof OPRD1, OPRK1, OPRL1 LPAR1 644/4885LPAR5 1129/4885TDP1 3340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.